🌐Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
🔴 Serious hazard — Reported risk: Според списъка на съставките, продуктът съдържа 2-(4-tert-бутилбензил)пропионалдехид (BMHCA - Lilial) и хидроксиизохексил 3-циклохексен карбоксалдехид (HICC), които са забранени в козметичните продукти. BMHCA може да увреди репродуктивната система, да увреди здравето на нероденото дете и да причини сенсибилизация на кожата. HICC може да причини алергична кожна реакция. Продуктът не съответства на Регламента за козметичните продукти.
Action taken by the authority
Type of economic operator taking notified measure
Distributor
Category of measure
Withdrawal of the product from the market
Date of entry into force
23/10/2025
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.
Product Name (original English): Eau De Parfum Spray Maison Alhambra Optus V
Risk Description (original English): According to the list of ingredients, the product contains 2-(4-tert-butylbenzyl)propionaldehyde (BMHCA - Lilial) and hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC), which are prohibited in cosmetic products. BMHCA may damage the reproductive system, harm the health of the unborn child and cause skin sensitisation. HICC may cause an allergic skin reaction.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.